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Vpr is one of the most enigmatic viral auxiliary proteins of HIV. During the past twenty years, several activities have
been ascribed to this viral protein, but one, its ability to mediate cell cycle arrest at the G2 to M transition has been
the most extensively studied. Nonetheless, the genuine role of Vpr and its pathophysiological relevance in the viral
life cycle have remained mysterious. Recent work by Laguette et al. (Cell 156:134-145, 2014) provides important
insight into the molecular mechanism of Vpr-mediated G2 arrest. This study highlights for the first time how Vpr
recruits the SLX4 endonuclease complex and how Vpr-induced inappropriate activation of this complex leads to G2
arrest. Here, we will discuss these findings in the light of previous work to show how they change the view of Vpr’s
mechanism of action. We will also discuss how these findings open new questions towards the understanding of
the biological function of Vpr regarding innate immune sensing.
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HIV type 1 and type 2 primate lentiviruses encode a set
of auxiliary proteins that differ between the two lenti-
viral lineages. Vpr, Nef and Vif are expressed by both the
HIV-1/SIVcpz and HIV-2/SIVsmm lineages, while Vpu is
specific to the former and Vpx to the latter. These auxil-
iary proteins play a crucial role at the host-virus inter-
face by modulating the intracellular micro-environment
in favor of viral infection and dissemination [1]. So far,
much work conducted to decipher their mechanism of
action has helped to understand the molecular steps
faced by HIV during the viral life cycle. Most HIV auxil-
iary proteins use the same strategy, i.e. hijacking a ubi-
quitin ligase complex, to target cellular proteins, the
so-called restriction factors, for proteasome-mediated
degradation. This is how HIV-1 Vpu, Vif or HIV-2/SIVsmm
Vpx counteract tetherin/BST-2, APOBEC3G and SAMHD1
respectively [2]. Each cellular target displays specific and
potent antiviral activity; de facto, some in vitro systems, in
which the restriction factor is expressed, can recapitulate
the dependence of infection on the viral protein. Alike Vpu,
Vif or Vpx, we and others have previously shown that HIV-* Correspondence: florence.margottin-goguet@inserm.fr
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unless otherwise stated.1 Vpr is also able to recruit a ubiquitin ligase complex, but
the significance of such an interaction has remained un-
known [3].
Expression of Vpr in cycling cells triggers cell cycle ar-
rest at the G2 phase, prior to mitosis. Vpr-mediated G2
arrest was revealed in 1995 by several groups [4-8] and
represents the most widely described property of the
viral protein. However, the biological significance of this
activity towards infection has been unclear for years
given that efficient viral replication does not require Vpr
in dividing cells. Paradoxically, a lack of Vpr slightly af-
fects viral infection in macrophages that do not divide
[9-12], suggesting that Vpr-mediated cell cycle arrest is
irrelevant to its role towards infection in these cells.
The recent study by Laguette and collaborators [13]
provides new information on the G2-arrest mechanism
induced by Vpr by highlighting its connection with the
SLX4 endonuclease complex (SLX4com), and in addition,
reports a potential anti-immune role for Vpr via this
interaction.Review
Hijacking DCAF1/VprBP in S-phase to induce cell cycle
arrest at the G2/M transition
In an attempt to decipher the molecular mechanisms
underlying Vpr-mediated G2 arrest, several studies havel. This is an Open Access article distributed under the terms of the Creative
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checkpoint network. This pathway involves the activa-
tion of ATR (Ataxia Telangiectasia-mutated and Rad3-
related) and Chk1 kinases and ends-up with the
inactivation of the cyclinB-Cdk1 complex, which gov-
erns mitosis entry [14-19]. In cooperation with its
downstream effectors, ATR preserves genome stability,
in particular by helping stalled replication forks to
proceed following genotoxic stress [20]. Vpr-mediated
induction of replication stress was observed in trans-
formed cell lines but also in primary CD4+ T cells and
correlates with the accumulation of replication protein
A, which binds single stranded DNA following replica-
tion stress [19]. In good agreement, the pathway used
by Vpr was also shown to result from an S phase-
dependent mechanism and to involve association of Vpr
with chromatin [19,21-23]. Yet, the precise mechanism
by which Vpr caused DNA replication stress and the
role of this stress during the course of the infection has
remained elusive.
In 2007, Vpr binding protein (VprBP), later on renamed
DCAF1 for DDB1-Cul4A-associated factor 1 (DDB1:
DNA damage-binding protein 1, Cul4A: Cullin 4A) was
recognized as a critical host factor in the ability of Vpr
to trigger cell cycle arrest [22,24-29]. Prior to this,
DCAF1/VprBP was first identified as a cellular protein
binding to Vpr with high affinity [30] and ten years
after, characterized as an adaptor of DDB1-Cul4 ubiqui-
tin ligases [31-34]. The data collectively obtained by the
different groups supported a model [22,24-28] in which
Vpr simultaneously recruits the Cul4A ubiquitin ligase
through DCAF1 and a so far unknown cellular protein
required for entry into mitosis. As a result, the Vpr tar-
get protein was supposed to be ubiquitinated and de-
graded to subsequently trigger G2 arrest. Vpr itself was
predicted to escape from DCAF1-induced degradation
and even to be stabilized by its association with the
Cul4A-DDB1 ubiquitin ligase [35]. In view of the model
of ubiquitin ligase hijacking for the benefit of the viral
cycle, we and others have hypothesized that the func-
tion of Vpr was dependent on the degradation of a spe-
cific host protein rather than the resulting G2 arrest
that could be a side effect in cycling cells. In this case,
we expected the host target of Vpr to be a negative factor
for viral replication [3]. For many investigators, identifica-
tion of the host protein(s) targeted for degradation by Vpr
became a priority toward understanding the genuine func-
tion of this viral protein.
Revisiting Vpr-mediated G2 arrest mechanism within the
context of SLX4
Following tandem affinity purification, immunoprecipita-
tion and mass spectrometry, Laguette et al. identified
structure-specific endonucleases (SSEs), namely ERCC1-ERCC4/XPF and MUS81-EME1, together with the SLX4
scaffold protein as new Vpr interacting partners [13]. Gly-
cerol gradient sedimentation and co-immunoprecipitation
studies confirmed that SLX4 subunits, DCAF1 and Vpr
assemble into a single complex. SLX4, also known as
BTBD12, was renamed FANCP, when biallelic muta-
tions in the SLX4 gene were associated with Fanconi
anemia (FA), an autosomal recessive genetic disorder
characterized by congenital abnormalities, bone marrow
failure and cancer susceptibility [36-39]. SLX4 provides
a molecular platform to form a complex (SLX4com)
with several SSEs, ERCC1-ERCC4/XPF, MUS81-EME1,
but also SLX1, and stimulates their activities to coordin-
ate the repair of specific replication-born double strand
breaks (DSBs) and collapsed replication forks [38-40].
MUS81-EME1 and SLX1 are specifically dedicated
to the resolution of replication-induced X-shaped DNA
structures, the so-called Holliday Junctions, during ho-
mologous recombination [41-43]. These SSEs are sub-
mitted to strict regulations along the cell cycle to ensure
the formation of an active complex at the right time and
subsequently the removing of inadequate DNA recom-
bination intermediates before chromosome segregation
[41,44-48] (Figure 1). Laguette et al. observed that Vpr in-
duces a slight decrease in EME1 and MUS81 expression
and an increase in the levels of polo-like kinase 1 (PLK1)
and phospho-PLK1, a kinase that activates the endonucle-
ase activity of EME1 through its phosphorylation [39,45].
In parallel, Vpr caused a remodeling of SLX4com through
its association with phospho-EME1 and the DCAF1 ubi-
quitin ligase (Figure 1). Importantly, time course experi-
ments led to the conclusion that Vpr-induced activation
of SLX4com precedes G2/M arrest and is not a conse-
quence of the cell cycle arrest per se. In addition, SLX4
purified in the presence of Vpr had increased cleavage ac-
tivity toward radiolabelled DNA substrates as compared
to the endonuclease in the absence of Vpr. Interestingly,
Vpr-mediated increase of SLX4com activity was abol-
ished when MUS81 expression was silenced. Import-
antly also, downregulation of SLX4, EME1 or MUS81
expression inhibited Vpr-mediated G2 arrest, which has
been recently confirmed by Berger et al. [49]. Collec-
tively, the data support a model in which Vpr induces
the premature activation of SLX4com, leading to repli-
cation stress as asserted by the appearance of FANCD2
foci [50]. Consequently, the abnormal cleavage of DNA
replication intermediates would presumably cause a G2
arrest. It is unclear yet whether this process is related to
previous observations suggesting that Vpr induces
double-strand breaks (DSB) formation or that MUS81
plays a role in the formation of such breaks in response
to the inhibition of replication [51,52]. Moreover, the
interaction of SLX4com with chromatin in the presence
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Figure 1 Model for Vpr-mediated G2 arrest through remodeling of the SLX4 complex. In a physiological contex activation of the SLX4
complex (SLX4com) intervenes to allow the resolution of DNA replication intermediates, such as Holliday Junctions (HJ), found in collapsed
replication forks after DNA replication (phases of SLX4 activation are symbolized by green arrows). This leads to a proper G2/M phase transition
(left panel). HIV-1 Vpr protein interacts with SLX4 on its SLX1 binding domain, the CUL4A–DDB1DCAF1 ubiquitin ligase and PLK1/p-PLK1. These
interactions lead to MUS81 ubiquitination, and phosphorylation of EME1 by p-PLK1, resulting in aberrant activation of SLX4com. This inappropriate
activation perturbs progression of ongoing replication forks (RF) in S phase and the resolution of abnormal DNA replication intermediates. As a
consequence, cells arrest at the G2 phase of the cell cycle (right panel).
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sociation with SLX4 and this interaction was enhanced
with Vpr. Given its role in Vpr-mediated G2 arrest, the
role of DCAF1 in SLX4com activation was further in-
vestigated. Silencing of DCAF1 reduced the accumulation
of PLK1 and Phospho-PLK1 seen in the presence of Vpr
and inhibited the reduction in MUS81 levels. In addition,
more ubiquitinated MUS81 species were detected with wt
Vpr, by comparing with the DCAF1-binding deficient Vpr
mutant (Q65R), which did not induce FANCD2 foci accu-
mulation. Nonetheless, whether the proteasome pathway
is involved in this process remains to be investigated with
the use, for example, of proteasome inhibitors. Altogether
the results suggest that Vpr uses DCAF1 for SLX4com ac-
tivation and reduction of MUS81 levels.
Vpr-mediated downregulation of MUS81 expression
seems relatively inefficient. One explanation could be
that degradation occurs in a short window of cell cycle
progression, just before G2/M, making it difficult to
highlight in asynchronous cells. Moreover, how degrad-
ation of MUS81 intervenes in the process of SLX4com
activation remains unclear. As a viral protein hijacking a
ubiquitin ligase, Vpr was initially thought to trigger the
degradation of an antiviral factor. Here, the ubiquitinationand the downregulation of MUS81 by Vpr could lead to
envision it as a potential antiviral factor counteracted by
Vpr and whose degradation would lead to G2 arrest. How-
ever, this is not the case, MUS81 depletion does not mimic
a G2 arrest phenotype and MUS81 or SLX4 depletion re-
duces viral infection, which indicates their positive role for
the viral life cycle. Nonetheless, it is intriguing that
MUS81 is both required for G2 arrest and also inactivated
by Vpr through DCAF1. Further studies will help to
understand the orchestration of these different events.
Though the SLX1 SSE does not co-purify with Vpr and
SLX4, SLX1 seems to participate in Vpr-mediated G2 ar-
rest. Indeed, depletion of SLX1 reduces the ability of Vpr
to mediate G2 arrest. In addition, purified SLX4com
isolated from Vpr expressing cells still processes SLX1
substrates. Of note, Vpr interacts with the SLX1 binding
domain of SLX4, which may indicate that interaction of
SLX4 with SLX1 and with Vpr are exclusive. These ap-
parently contradictory findings may reflect that a series
of complex and successive events are involved in Vpr-
mediated SLX4 activation.
Recent work by Berger et al. further supports a role of
SLX4, MUS81 and EME1 in Vpr-mediated G2 arrest
[49]. Interestingly, SIV Vpr alleles competent for G2
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alleles incompetent for G2 arrest in those cells. SIV Vpr
alleles competent for G2 arrest in Grivet cells, but not in
human cells, interact with simian SLX4. This species-
specificity in Vpr-mediated G2 arrest supports the idea
of a central role of SLX4 in Vpr function.
Altogether the results by Laguette et al. support a
model in which Vpr forces activation of the SLX4 com-
plex, rather than supporting the previous model in
which Vpr eliminates an antiviral factor. Nonetheless, we
are tempted to put forward the hypothesis that the two
models could be reconciled in a model in which Vpr
would for example induce the degradation of an inhibi-
tor of SLX4 activation that has potent antiviral activity.
Vpr and escape from immune sensing
Persistent viruses such as HIV are known to interfere
with the overall immune host response [53]. The role of
Vpr in this context has been studied by several groups.
Namely, two reports have previously demonstrated that
Vpr decreases the expression of IRF3, an essential pro-
tein for interferon (IFN) beta production in response to
viral infection [54,55]. Furthermore, numerous immuno-
suppressive activities of Vpr have been identified, includ-
ing its capacity to perturb the Th1 lymphocytes activity
or the Treg homeostasis [56,57]. Altogether, these stud-
ies highlight a new capacity of Vpr to participate in the
viral persistence by hindering the appropriate cooper-
ation between immune cells. In Laguette et al., deletion
of Vpr induces a 2 to 3 fold increase of the expression of
mRNA of the type 1 interferon response (IFNα, IFNβ
and MxA) upon HIV-1 infection in HeLa cells, support-
ing the notion that Vpr could contribute to HIV-1 es-
cape from innate immune sensing. Nonetheless, whether
reduction in IFN-related mRNAs in the presence of Vpr
is related to SLX4 remains difficult to assess since dele-
tion of SLX4 or MUS81 alone leads to a huge increase
of the same mRNAs. Interestingly though, the authors
showed that HIV-1 DNA products of reverse transcrip-
tion are pulled down with epitope-tagged SLX4 specific-
ally in the presence of Vpr and that reduction of SLX4
expression leads to an increase in HIV-1 DNA levels.
These results suggest that Vpr could help to escape im-
mune sensing by inducing the digestion of viral DNA
through SLX4com activation (Figure 2).
Surprisingly, the increase in HIV-1 DNA levels under
SLX4 knock-down is not associated with an increase in
HIV-1 infection, however it should be stressed that the
forms accumulated under SLX4 knock-down are not
fully characterized yet and could correspond to abortive
products of reverse transcription. It is also puzzling that
no RT product is detected in the SLX4 immunoprecipi-
tate a few hours after infection as we could expect from
previous studies [58]. Given the presence of SLX4 intothe nucleus, its association with 1/2LTR circles or even
proviruses would be worth to look at deeply.
In a model in which SLX4 would play a role in the es-
cape from immune sensing by digesting viral DNA,
depletion of SLX4 should reduce viral infection. Accord-
ingly, cells from FANCP patients or MEF cells depleted
for SLX4 displayed high levels of IFNα, IFNβ and Mxa
mRNA and a decreased permissivity to viral transduc-
tion. Of note, the decrease in HIV-1 infection under
SLX4 depletion was seen in patient samples but not in
HeLa cells depleted for SLX4 or MUS81. Why the high
increase in IFN-related mRNAs in HeLa cells does not
correlate with an inhibition of HIV-1 transduction in
these same cells is puzzling. In other circumstances, pro-
duction of IFN inhibits HIV-1 transduction in single-
cycle infection experiments, for instance following
depletion of the TREX1 endonuclase [59]. Several hy-
potheses can account for the lack of effect of Vpr on
HIV-1 infection in HeLa cells. Though an effect on IFN-
related mRNA levels is detected, it is likely that this ef-
fect does not lead to efficient interferon production, as it
could be the case in other primary cells. Alternatively,
the production of IFN might be too weak to have a
negative effect on single-round infection, but would be
cumulative in a spreading infection using replicative vi-
ruses. In this setting also, it is likely that HeLa cells do
not have all the connections that allow efficient IFN sig-
naling for subsequent HIV-1 infection inhibition. Sur-
prisingly, a recent report has provided evidence that
HIV-1 Vpr induces Interferon-Stimulated Genes (ISG)
and helps to activate innate immune response in non-
infected macrophages [60]. These apparent discrepancies
may result from the use of different cellular systems,
non-infected macrophages versus infected Hela cells.
Further experiments by additional investigators will help
to draw a clearer picture of what is going on under Vpr
treatment in different cell types.
Previous work has demonstrated how a subset of Vpr
proteins from lentiviruses lacking the auxiliary protein
Vpx were still able to degrade the antiviral factor
SAMHD1 as well as Vpx from HIV-2/SIVsmm/SIVmac
[61-63]. Alike SLX4, SAMHD1 modulates the DNA
damage response [64]. Mutations of SAMHD1 are found
in the Aicardi-Goutières syndrome (AGS), a rare auto-
somal recessive genetic encephalopathy characterized by
high levels of IFN leading to chronic inflammation [65].
Several studies indicate that SAMHD1 limits proinflam-
matory cytokine production and immune detection
[65-70]. Inhibition of the immune sensing of HIV-1
through SAMHD1 results from the dNTPase activity of
the protein, which contributes to the removal of nucleo-
tides essential for viral cDNA synthesis in myeloid cells
and quiescent CD4+ T cells, but could also potentially




































Figure 2 Model for Vpr-mediated evasion from immune sensing. The model envisioned by Laguette et al. proposes that HIV DNA forms
accumulate following infection by a Vpr-deleted HIV-1 virus (HIV-1ΔVpr). These forms, that are not characterized, are sensed by a DNA immune
sensor to generate an IFN response (left panel). A Vpr encoding HIV-1 virus would instead force the SLX4com endonuclease activity. The subsequent
processing of extra reverse transcription products would help to prevent their accumulation and allow escape from immune sensing (right panel).
How does SLX4com distinguish between the unproductive and the productively infecting RT intermediates is unknown. In addition, whether Vpr
increases the efficiency of viral infection by activating SLX4 has not been investigated yet.
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subset of other lentiviruses have kept the ability to de-
grade SAMHD1, in order to increase dNTP levels for ef-
ficient reverse transcription, even at the expense of the
possibility to escape immune detection. Strikingly, HIV-1
Vpr and HIV-2/SIVsmm Vpx seem to function in opposite
directions with respect to immune sensing. Altogether, by
having no Vpx but one Vpr, HIV-1 has significant assets
to escape immune detection compared to HIV-2. In
addition, HIV-2 capsid harbors a major determinant for
viral cDNA sensing, while HIV-1 capsid has been shown
to prevent sensing or even to bind specific cofactors to
evade immune detection [78-80]. Differences in escape
from immune sensing likely contribute to the different
pathogenic outcomes associated with the two viruses,
HIV-1 being far more pathogenic than HIV-2 [81].
Other host proteins than SAMHD1 contribute to limit
the sensing of viral nucleic acids, including RNASEH2,
which degrades DNA:RNA hybrids or TREX1, which
eliminates viral DNA in excess [82-85]. Importantly, genesencoding for TREX1 and RNASEH2 are also mutated in
the Aicardi-Goutière syndrome (AGS), highlighting
how these proteins provide a link between autoimmun-
ity and nucleic acid metabolism [62,63,86-88]. This is
also supported by their capacity to control endogenous
retrotransposition [89-91]. An interesting possibility is
that endogenous retroelements, alike abnormal replica-
tion intermediates, could trigger the activation of SLX4,
a mechanism that would in turn lead to chronic inflam-
mation in FA disease.
Once activated, how does SLX4 distinguish “good DNA”
that will lead to productive infection, from “bad DNA”
that will be destroyed? Such a question has already been
brought up regarding TREX1 [92]. One hypothesis is that
only non-productive short DNA generated by errors dur-
ing reverse transcription may be targeted by nucleases. Al-
ternatively, access to the viral DNA may be governed by
the stability of the capsid core that is implicated in the
control of reverse transcription [93-95]. In any event,
identification of immune sensors associated to this process
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from the innate immune response. Whether the recently
identified DNA sensors of HIV are specifically recruited in
the absence of Vpr but not in its presence should be fur-
ther addressed [78,96,97].
Another intriguing question concerns the presence or
not of a signature of positive selection in SLX4. Such
signature characterizes restriction factors and corre-
sponds to variations in their sequences at the interface
with the viral protein, reflecting an evolutionary arms-
race between the virus and its host [98]. Recent work
has shown how these sequence variations contribute to
host susceptibility to viral infection. Here regarding the
interplay between Vpr and SLX4, we are facing a new
situation since SLX4 is not an antiviral factor, but is ra-
ther beneficial for the virus. One may speculate that co-
evolution would push SLX4 to avoid Vpr in order to
restore an immune response, while Vpr would evolve to
conserve its association with SLX4.
Vpr, SLX4com and a cellular system relevant for Vpr’s
study
Future work should aim at elucidating whether Vpr pro-
vides an advantage to viral infection by activating SLX4.
Thus, an important issue is to analyze whether the delta-
Vpr HIV-1 virus is similarly infectious in cells depleted or
not of SLX4 as the wt virus in SLX4−/− cells. The limiting
factor in such study is the choice of a cellular system in
which Vpr would clearly increase viral infection. So far,
macrophages have represented an appropriate system,
since in these cells, Vpr-deficient HIV-1 showed a slight
replication defect [9-12]. In contrast to previous findings,
one study has also reported that Vpr is able to enhance
HIV-1 infection in peripheral blood mononuclear cells
and dendritic cells [99]. More studies are needed to assess
what is the best in vitro cellular model in which replication
would depend on the presence of Vpr. In macrophages,
the question of the presence of SLX4 and the associated
nucleases has to be addressed before wondering whether
Vpr-mediated enhancement of macrophage infection is
linked to the activity of SLX4com. Of note, Zimmerman
et al. previously found that HIV-1 Vpr fails to induce acti-
vation of the ATR pathway in macrophages, due to the
lack of protein expression of at least ATR, Chk1 and
Rad17 [19]. However, the question is still open regarding
SLX4com. If SLX4 drives HIV-1 Vpr function in certain
cell types such as macrophages, then, one would like to
know whether differences of Vpr alleles to activate SLX4
correlate with different capabilities to help macrophage
infection.
Conclusions
The study from Laguette et al. provides important in-
sights into the mechanism of Vpr-mediated G2 arrestwith the identification of SLX4com as a new functional
partner of Vpr. This discovery also opens new avenues
to understand the biological role for Vpr along the viral
life cycle. The idea that HIV may have developed a pro-
tein to induce the degradation of its own viral DNA
leads to the intriguing questions of how the virus can
achieve the right balance between preservation of viral
DNA synthesis and escape from immune sensing
through viral DNA degradation. In recent years, immune
sensing has taken on a growing role in our understand-
ing of the battle between the virus and the cell, making
it important to identify the molecular players at stake
such as SLX4com. Research associated to other diseases,
namely AGS and FA, will certainly benefit from these
discoveries.
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